The independent effect of drug resistance on T cell activation in HIV infection
- 21 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (5) , 691-699
- https://doi.org/10.1097/01.aids.0000216369.30948.18
Abstract
Objective: Antiretroviral-treated individuals with drug-resistant HIV experience slower CD4 cell count declines than untreated individuals, independent of degree of viremia. As immune activation independently predicts disease progression, we hypothesized that patients with drug-resistant viremia would have less immune activation than patients with wild-type viremia, independent of plasma HIV RNA levels and that these differences would not be explained by a direct drug effect of protease inhibitors. Methods: Percentages of activated (CD38/HLA-DR) T cells were compared between untreated participants with wild-type viremia and antiretroviral-treated participants with drug-resistant viremia, after adjusting for plasma HIV RNA levels among other factors associated with T cell activation. Changes in T cell activation were also assessed in subjects discontinuing protease inhibitors while continuing other antiretroviral medications. Results: Twenty-one untreated participants with wild-type viremia and 70 antiretroviral-treated participants with drug-resistant viremia were evaluated. Relative to untreated participants, those with drug-resistant viremia had 29% fewer activated CD4 (P = 0.051) and CD8 (P = 0.012) T cells after adjustment for plasma HIV RNA levels among other factors. There was no evidence for an early change in T cell activation among 13 subjects with drug-resistant viremia interrupting protease inhibitors while continuing other antiretroviral medications, but a significant increase in T cell activation with complete or partial emergence of wild-type sequences in protease. Conclusions: Antiretroviral-treated patients with drug-resistant viremia have less T cell activation than untreated patients, independent of plasma HIV RNA level. Decreased ability of drug-resistant variants to cause T cell activation likely contributes to slower CD4 cell count declines among patients with drug-resistant viremia.Keywords
This publication has 46 references indexed in Scilit:
- Extracellular Nef Protein Targets CD4+T Cells for Apoptosis by Interacting with CXCR4 Surface ReceptorsJournal of Virology, 2004
- Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular ImmunityJournal of Virology, 2003
- Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus–Infected Patients with Very Low CD4 Cell CountsThe Journal of Infectious Diseases, 2002
- Reduced Levels of CD4 Cell Spontaneous Apoptosis in Human Immunodeficiency Virus–Infected Patients with Discordant Response to Protease InhibitorsThe Journal of Infectious Diseases, 2002
- Effects of Antiretroviral Drugs on Human Immunodeficiency Virus Type 1-Induced CD4+T-Cell DeathJournal of Virology, 2002
- CD4+T Cell Kinetics and Activation in Human Immunodeficiency Virus–Infected Patients Who Remain Viremic Despite Long‐Term Treatment with Protease Inhibitor–Based TherapyThe Journal of Infectious Diseases, 2002
- Decreased HIV-Associated T Cell Apoptosis by HIV Protease InhibitorsAIDS Research and Human Retroviruses, 2000
- Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4European Journal of Immunology, 1997
- HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by ‘tissue’ transglutaminase expression and prevented by cyclosporin AFEBS Letters, 1994
- Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.The Journal of Experimental Medicine, 1992